memo - Magazine of European Medical Oncology最新文献_第2页

HER2 in focus—gastric cancer 聚焦 HER2--胃癌

IF 0.6

memo - Magazine of European Medical Oncology Pub Date : 2023-12-01 DOI: 10.1007/s12254-023-00925-x

Aysegül Ilhan-Mutlu

引用次数: 0

ASCO 2023—partnering with patients: the cornerstone of cancer care and research ASCO 2023--与患者合作：癌症护理和研究的基石

IF 0.6

memo - Magazine of European Medical Oncology Pub Date : 2023-12-01 DOI: 10.1007/s12254-023-00930-0

Gabriel Rinnerthaler

引用次数: 0

A CONGRESS DIGEST ON RADIOLABELED THERANOSTICS FOR SOLID TUMORS. Report from the 36th Annual Congress of the European Association of Nuclear Medicine (EANM), September 9th – 13th, 2023, Vienna 关于实体瘤放射性标记疗法的大会摘要。欧洲核医学协会（EANM）第 36 届年会报告，2023 年 9 月 9 日至 13 日，维也纳

IF 0.6

memo - Magazine of European Medical Oncology Pub Date : 2023-12-01 DOI: 10.1007/s12254-023-00940-y

引用次数: 0

Prostate cancer special—part 1 前列腺癌专题--第 1 部分

IF 0.6

memo - Magazine of European Medical Oncology Pub Date : 2023-12-01 DOI: 10.1007/s12254-023-00923-z

S. Shariat

引用次数: 0

Supportive management 支持性管理

IF 0.6

memo - Magazine of European Medical Oncology Pub Date : 2023-12-01 DOI: 10.1007/s12254-023-00926-w

Christoph Minichsdorfer, PhD

引用次数: 0

A GLOBAL CONGRESS DIGEST ON LUNG CANCER. Report from the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer, September 9th-12th , hybrid congress 全球肺癌大会摘要。来自国际肺癌研究协会（IASLC）2023 年世界肺癌大会（9 月 9 日至 12 日，混合大会）的报告

IF 0.6

memo - Magazine of European Medical Oncology Pub Date : 2023-11-28 DOI: 10.1007/s12254-023-00939-5

MD Alex A. Adjei, MD Luana Calabró, Maria Rosario, MD Garcia Campelo, MD Federico Cappuzzo, MD Michaël Duruisseaux, MD Wolfgang Hilbe, MD Maximilian Hochmair, MD Maarten Lambrecht, MD Herbert H F Loong, MD Stephen V. Liu, MD Filippo de Marinis, MD Frcpc Barbara Melosky, PhD Luis Montuenga, MD Nir Peled, MD Robert Pirker, MD Jordi Remon, MD Lung Clinic Grosshansdorf Martin Reck, MD Lung Cancer Group Cologne Matthias Scheffler, PhD Frcp Riyaz Shah, PhD Yu Shyr, MB Ross Soo, MD Alexander Spira, MD Masahiro Tsuboi, M. H. William N. William, Beneficência Portuguesa de, São Paulo, Brazil Yi-Long, MD Facs Wu, PhD Anna Fenzl, MD Navneet Singh, MD. Judith Moser

引用次数: 0

Decitabine combined with low-dose cytarabine, aclarubicin and rhG-CSF regimen may be a potential alternative for relapsed/refractory acute myeloid leukemia: A single-center study 地西他滨联合低剂量阿糖胞苷、阿克拉比星和 rhG-CSF 方案可能是治疗复发/难治性急性髓性白血病的潜在替代方案：一项单中心研究

IF 0.6

memo - Magazine of European Medical Oncology Pub Date : 2023-11-20 DOI: 10.1007/s12254-023-00933-x

Yu Fu, Long Su, Yuying Li, Yehui Tan

引用次数: 0

Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer 来自ASCO 2023的原发性可切除和晚期或转移性胰腺癌的重要新闻

memo - Magazine of European Medical Oncology Pub Date : 2023-11-13 DOI: 10.1007/s12254-023-00931-z

Patrick Reimann, Thomas Winder

引用次数: 1

Focal therapy in intermediate- and high-risk prostate cancer 中高危前列腺癌的局灶治疗

memo - Magazine of European Medical Oncology Pub Date : 2023-11-10 DOI: 10.1007/s12254-023-00932-y

Nicolai A. Huebner, Stephan Korn, Pawel Rajwa, Shahrokh F. Shariat

{"title":"Focal therapy in intermediate- and high-risk prostate cancer","authors":"Nicolai A. Huebner, Stephan Korn, Pawel Rajwa, Shahrokh F. Shariat","doi":"10.1007/s12254-023-00932-y","DOIUrl":"https://doi.org/10.1007/s12254-023-00932-y","url":null,"abstract":"Summary Focal therapy is a treatment option for clinically localized prostate cancer, finding increased use in recent years. It is generally associated with very good functional outcome regarding pad-free continence and preservation of erections. Oncologic outcomes are controversial, especially depending on the ideal endpoint. Both the presence of clinically significant prostate cancer (csPCA) on biopsy and the absence of any whole-gland or systemic treatment as “failure-free survival” (FFS) have been used. While salvage whole-gland and systemic therapy is rare, a substantial number of patients will have csPCA on follow-up biopsies after focal therapy, either in-field or out of field. Generally, patients selected for focal therapy are considered intermediate-risk, although some patients with high-risk features have been included into focal therapy studies. With the data currently available focal therapy presents a good treatment option for patients with feasible intermediate-risk prostate cancer, interested in functional outcome, after proper counseling on the higher recurrence rate, and the need for surveillance biopsies during follow-up.","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"113 52","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135137266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Renal crystal-storing histiocytosis successfully treated with bortezomib-based regimen 硼替佐米为基础的方案成功治疗肾结晶性组织细胞增多症

memo - Magazine of European Medical Oncology Pub Date : 2023-11-07 DOI: 10.1007/s12254-023-00922-0

Poornima Tadkal, Siddini Vishwanath, Vankalakunti Mahesha, Kishore Babu, Mallikarjun Kalashetty

引用次数: 0